Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

79.07 +0.36 (+0.46%)
Streaming Delayed Price Updated: 11:44 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,333,777
Open 79.62
Bid (Size) 79.06 (3)
Ask (Size) 79.07 (1)
Prev. Close 78.71
Today's Range 79.00 - 79.81
52wk Range 60.47 - 80.86
Shares Outstanding N/A
Dividend Yield 1.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga

Performance

YTD
+15.60%
+15.60%
1 Month
+0.24%
+0.24%
3 Month
+12.75%
+12.75%
6 Month
+17.77%
+17.77%
1 Year
+14.73%
+14.73%

More News

Read More
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Via Benzinga
Topics ETFs
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
Via InvestorPlace
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
Via Benzinga
Exposures COVID-19
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
Via Benzinga
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
Via Benzinga
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
Via InvestorPlace
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Via InvestorPlace
The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits
Via InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Via MarketBeat
Topics Economy
Exposures Interest Rates
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.